Randomized Trial Finds CBD Use Associated with Liver Enzyme Elevations in Healthy Adults
Disclosure: CBDworldnews.com participates in affiliate programs and may earn a commission on purchases made through links on this site. This does not influence our editorial coverage.
Cannabidiol (CBD) has become one of the fastest-growing wellness supplements in the United States — but how much do we actually know about its safety? A new randomized, double-blind, placebo-controlled clinical trial published in JAMA Network Open is raising important questions, finding measurable changes in liver enzyme levels among healthy adults using CBD. For the millions of Americans who take CBD daily without medical supervision, this study is worth understanding.
The findings land at a critical moment. The CBD market has exploded into a multi-billion-dollar industry with products ranging from gummies and tinctures to beverages and topicals — most sold over the counter with minimal regulatory scrutiny. Yet rigorous, large-scale clinical safety data has remained remarkably sparse. This trial begins to fill that gap, and what it reveals about liver health deserves serious attention from consumers and clinicians alike.
The study, conducted between January and August 2024 at Spaulding Clinical Research in West Bend, Wisconsin, tracked liver function markers in participants assigned to receive CBD or placebo. Researchers observed elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) — enzymes commonly used to assess liver health — in some CBD users compared to the placebo group. The trial also documented increased eosinophilia (elevated eosinophils, a type of white blood cell) in participants using CBD.
“The findings suggest a need for more comprehensive investigation into CBD’s long-term effects and its safety profile in specific populations,” the study’s authors noted, calling for further research into how typical consumer dosing patterns and duration of use may influence these outcomes.
Important Context on Dosing and Clinical Significance
The trial employed CBD doses and monitoring protocols specific to a controlled clinical research environment. The enzyme elevations observed do not necessarily reflect what occurs at the lower doses commonly used by everyday consumers, and the clinical significance of these changes has not been fully established. Readers should resist the impulse to extrapolate these findings directly to over-the-counter use without that nuance.
That said, the signal cannot be dismissed. Even subclinical enzyme elevations can carry meaning for individuals with pre-existing liver conditions, impaired metabolism, or those taking medications processed by the liver — including common drugs such as statins, anticoagulants, and certain antidepressants. The authors specifically flag these populations as warranting heightened caution.
What the Research Gap Means for Consumers
Most available CBD safety evidence continues to come from small studies, animal models, or laboratory settings — leaving substantial uncertainty about how findings translate to real-world use, where dosages, product quality, purity, and duration of use vary enormously. This trial represents meaningful progress, but it is one data point, not a verdict.
The research reinforces a broader structural problem: the CBD market has scaled far ahead of the regulatory and scientific infrastructure designed to protect consumers. Products are widely available without standardized dosing guidance, mandatory third-party testing requirements, or clear labeling on drug interactions. The authors call explicitly for standardized safety guidelines as the market continues to expand.
“These findings reinforce that CBD is not universally risk-free and that individual responses may vary,” the researchers concluded, advocating for additional studies examining vulnerable populations and real-world usage patterns.
The Bottom Line
This trial will not — and should not — send consumers running from CBD. But it does make one thing clear: treating CBD as a consequence-free supplement is no longer scientifically defensible. The evidence now supports a more informed, cautious approach. If you use CBD regularly, discussing that use with your doctor is not overcaution — it is basic due diligence, particularly if you have any liver history or take prescription medications. As regulatory agencies and researchers work to establish clearer safety standards, staying informed and proactive is the most protective thing a consumer can do.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
CBDworldnews.com reports on the CBD industry for informational and educational purposes only. Nothing on this site constitutes medical advice. Consult a qualified healthcare professional before starting or modifying any CBD regimen, particularly if you have liver conditions, take prescription medications, or are pregnant or nursing. Always disclose CBD use to your physician.
